A Part of the University of Maryland Medical Center

• Genitourinary Oncology

• Patient Care
• Diagnostic and Treatment Services
• Physicians and Staff
• Prostate Health Glossary
• Trilogy Radiation Therapy
• Robotic Prostatectomy
• Prostate Seed Implants
• Patient Education...
• 
    Related Resources
• Clinical Trials
• Information for Patients
• The Maryland Prostate Center

• Bladder and Other Urothelial Cancers Screening
• Bladder Cancer Treatment
• Childhood Extracranial Germ Cell Tumors Treatment
• Extragonadal Germ Cell Tumors Treatment
• Penile Cancer Treatment
• Prostate Cancer Prevention
• Prostate Cancer Screening
• Prostate Cancer Treatment
• Renal Cell Cancer Treatment
• Testicular Cancer Screening
• Testicular Cancer Treatment
• Transitional Cell Cancer (Kidney/Ureter) Treatment
• Urethral Cancer Treatment
• Wilms Tumor and Other Childhood Kidney Tumors Treatment

Prostate Seed Implants

Reports on the Effectiveness of Taxotere for Treating Prostate Cancer

1. DiPaola, R.S., Approaches to the treatment of patients with hormone-sensitive prostate cancer. Semin Oncol, 1999. 26(5 Suppl 17): p. 24-27.
   
   
2. Kang, M.H., W.D. Figg, and W. Dahut, Taxanes in hormone-refractory prostate cancer. Cancer Pract, 1999. 7(5): p. 270-72.
   
   
3. Milas, L., M.M. Milas, and K.A. Mason, Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol, 1999. 9(2 Suppl 1): p. 12-26.
   
   
4. Friedland, D., et al., A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol, 1999. 26(5 Suppl 17): p. 19-23.
   
   
5. Picus, J. and M. Schultz, Docetaxel (Taxotere) as monotherapy in the treatment of hormone- refractory prostate cancer: preliminary results. Semin Oncol, 1999. 26(5 Suppl 17): p. 14-18.
   
   
6. Petrylak, D.P., et al., Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol, 1999. 17(3): p. 958-67.
   
   
7. Petrylak, D.P., et al., Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol, 1999. 17(3): p. 958-67.
   
   
8. Kwok, Y., DiBiase, S.J., Amin, P.P., Naslund, M., Sklar, G., Jacobs, S.C.; Risk Group Stratification in Patients Undergoing Permanent Iodine 125 Prostate Brachytherapy As Monotherapy. Int.J.Radiation Oncology Biol.Phys., Vol. 53, No. 3, pp.588-594, 2002.
   
   
9. DiBiase, S.J., Dawson, N., Naslund, M., Hussain, A., Kataria, R., Bangalore, M., Dhople, A., Guo, C., and Amin, P.P.; Phase II Study of Combined External Beam Radiation Therapy (EBRT), Brachytherapy (PB), Total Androgen Suppression (TAS), and Adjuvant Docetaxel (AD) in Poor-Risk, Localized Prostate Cancer (PCa). Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol. 22, No. 14S (July 15 Supplement), 2004:4764.

This page was last updated on: March 5, 2008.

Please rate the quality of this article. Do you find this article to be helpful / informative?                Poor                                       Excellent Do you have any brief comments on this page: (up to 255 characters) Note: If you have a question, please contact Ask the Expert.

Email this Page                                                                     Print this Page